CORONARY HEART DISEASE OR HIGH RISK OF CORONONARY HEART DISEASE Clinical Trials

8 clinical trials for CORONARY HEART DISEASE OR HIGH RISK OF CORONONARY HEART DISEASE across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, INVESTIGATOR- AND PARTICIPANT-BLINDED PHASE 2A STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DFV890 FOR INFLAMMATORY MARKER REDUCTION IN ADULT PARTICIPANTS WITH CORONARY HEART DISEASE AND ELEVATED HSCRP — RECRUITING · PHASE2
• A PROSPECTIVE, COMPARATIVE, RANDOMIZED, MULTI-CENTER, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2A STUDY OF THE SAFETY AND EFFICACY OF CMX-2043 FOR PERIPROCEDURAL INJURY PROTECTION IN SUBJECTS UNDERGOING CORONARY ANGIOGRAPHY AT RISK OF RADIO-CONTRAST INDUCED NEPHROPATHY (CARIN) — RECRUITING · PHASE2
• ELIMINATE CORONARY HEART DISEASE — RECRUITING
• A RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, INVESTIGATOR- AND PARTICIPANT-BLINDED PHASE 2A STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DFV890 AND MAS825 FOR INFLAMMATORY MARKER REDUCTION IN AN ADULT POPULATION WITH CORONARY HEART DISEASE AND CLONAL HEMATOPOIESIS OF INDETERMINATE POTENTIAL (CHIP) — COMPLETED · PHASE2
• A PROSPECTIVE RANDOMISED, OPEN LABEL, BLINDED ENDPOINT (PROBE) STUDY TO EVALUATE DUAL ANTITHROMBOTIC THERAPY WITH DABIGATRAN ETEXILATE (110MG AND 150MG B.I.D.) PLUS CLOPIDOGREL OR TICAGRELOR VS. TRIPLE THERAPY STRATEGY WITH WARFARIN (INR 2.0 - 3.0) PLUS CLOPIDOGREL OR TICAGRELOR AND ASPIRIN IN PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION (NVAF) THAT HAVE UNDERGONE A PERCUTANEOUS CORONARY INTERVENTION (PCI) WITH STENTING. (RE-DUAL PCI) — COMPLETED
• A RANDOMIZED, DOUBLE-BLIND, EVENT-DRIVEN, MULTICENTER STUDY COMPARING THE EFFICACY AND SAFETY OF ORAL RIVAROXABAN WITH PLACEBO FOR REDUCING THE RISK OF DEATH, MYOCARDIAL INFARCTION OR STROKE IN SUBJECTS WITH CHRONIC HEART FAILURE AND SIGNIFICANT CORONARY ARTERY DISEASE FOLLOWING A HOSPITALIZATION FOR EXACERBATION OF HEART FAILURE. — COMPLETED
• MULTICENTER OPEN-LABEL STUDY TO EVALUATE EFFICACY OF GADOBUTROL-ENHANCED CARDIAC MAGNETIC RESONANCE IMAGING (CMRI) FOR DETECTION OF SIGNIFICANT CORONARY ARTERY DISEASE (CAD) IN SUBJECTS WITH KNOWN OR SUSPECTED CAD BY A BLINDED IMAGE ANALYSIS — COMPLETED
• AGGRESSIVE CHOLESTEROL THERAPY TO INHIBIT VEIN GRAFT EVENTS (ACTIVE TRIAL): DOES HIGH-DOSE POSTOPERATIVE STATIN THERAPY IMPROVE GRAFT PATENCY AFTER CORONARY BYPASS. — NOT_YET_RECRUITING

Refine this search